Localized ecthyma gangrenosum without sepsis in a neutropenic patient with a myelodysplastic syndrome—Refractory anemia with excess blasts type 2

Anaïs Zanella1,2 | Cyril Faure3 | Catherine Merle2 | Romain Charollais1,2 | François Aubin1

1Service de Dermatologie, CHU and EA3181, Besançon, France
2Service de Dermatologie, Centre Hospitalier de la Haute Saône, Vesoul, France
3Service d’Hématologie, Centre Hospitalier de la Haute Saône, Vesoul, France

Abstract
The diagnosis of ecthyma gangrenosum should be evoked in front of maculopapular lesions rapidly evolving to necrotic ulcers, particularly in the presence of prolonged neutropenia or other hematological malignancies.

Keywords
ecthyma gangrenosum, myelodysplasia, neutropenia

1 | INTRODUCTION

Ecthyma gangrenosum (EG) is a rare cutaneous infection most commonly associated with Pseudomonas aeruginosa bacteremia. The infection typically occurs in immunocompromised or neutropenic patients. We report the case of a patient with myelodysplastic syndrome, refractory anemia with excess blasts type 2, who developed a localized EG without bacteremia.

Ecthyma gangrenosum is a rare cutaneous infection most commonly associated with P. aeruginosa bacteremia.1,3 The infection typically occurs in immunocompromised or neutropenic or critically ill patients and warrants prompt diagnosis and treatment.

We report the case of an EG in a patient with myelodysplastic syndrome—refractory anemia with excess blasts type 2 (MDS EB1).

2 | CASE PRESENTATION

A 74-year-old man with a SMD EB1 treated by blood transfusion support, developed 2 days ago, two papular and erythematous cutaneous lesions, on both the left leg and thigh. These lesions were painful, evolving in one week into nodular lesions with ulceration and central necrosis (Figure 1). No causal factors were found. The patient was in fair condition, and he had no fever. Blood tests demonstrated a stable anemia and a neutropenia (0.2 G/L) as well as an elevated CRP (216 mg/mL). Cultured swabs were positive to P. aeruginosa. Different blood cultures were negative, consistent with nonbacteraemic EG. Treatment included intravenous amoxicillin-clavulanic acid (1 g × 3/d for 14 days). Within a few days, the lesions were much less painful and significant healing was noted (Figure 2).

3 | DISCUSSION

To our knowledge, there are few cases of nonbacteraemic cutaneous localized EG in patients with myelodysplastic syndrome—refractory anemia with excess blasts type 2. Indeed, myelodysplasia is often associated with lymphoma or acute leukemia and EG is then septicemic.
Ecthyma gangrenosum is a rare cutaneous manifestation of *Pseudomonas* infections.\textsuperscript{1-3} *Pseudomonas aeruginosa* is considered as an opportunistic bacteria that rarely causes infection in immunocompetent subjects.\textsuperscript{4,5}

*Pseudomonas aeruginosa* is a nonfermentative, mobile, Gram-negative rod able to produce hydrosoluble pigments (eg, pyocyanin) and different extracellular enzymes (eg, collagenase, elastase, and phospholipase), exotoxins, and endotoxins. EG usually occurs in immunocompromised patients, especially in diseases involving abnormal neutrophil function or in patients with granulocytopenia.

The lesions typically begin with bullae or hemorrhagic pustules that evolve into ulcerations and eschars surrounded by an erythematous halo. The diagnosis is based on the macroscopic aspect as well as on the clinical evolution of the lesions, blood cultures, skin biopsies, and bacteriological analysis of tissue specimen.

Differential diagnosis includes anthrax, erythema multiforme, Herpes infection, Sweet syndrome, and pyoderma gangrenosum.

The presence of *P aeruginosa* is a strong argument for the diagnosis, but several other bacterial and fungal pathogens have also been involved,\textsuperscript{5,6} including Gram-negative bacteria (*Aeromonas hydrophila*, *Escherichia coli*, *Citrobacter freundii*, and *Serratia marcescens*), Gram-positive cocci (*Staphylococcus aureus* and *Streptococcus pyogenes*), Gram-negative cocci (*Neisseria gonorrhoea*), and fungi (*Aspergillus* sp, *Fusarium solani*, *Candida* sp, and *Scytalidium dimidiatum*).

Of the 167 published EG cases recently analyzed, *P aeruginosa* was detected in 123 (73.65%), and other bacterial etiologies were detected in 29 cases (17.35%). Among the 123 EG cases with *P aeruginosa* etiology, sepsis was described in 72 cases (58.5%) and an absence of septicemia was reported for 51 cases (41.5%).\textsuperscript{7} Two distinct clinical presentations have been described: a cutaneous localized form\textsuperscript{5-8} and a septicemic form with a poor prognosis and a high mortality rate, around 60% in contrast to 15% for localized EG.\textsuperscript{5,6}

Classically, hematological seeding from the gastrointestinal, respiratory, and genitourinary tracts to the skin results in ulcer formation. Nonbacteraemic EG\textsuperscript{5-8} may result from direct inoculation of the skin, or possibly through undetected low-grade transient bacteraemia.

Although empirical systemic antibiotics should include antipseudomonal coverage and wound care, there are no specific guidelines in the literature. Bodey et al\textsuperscript{9} reported an overall cure rate of 67% for patients receiving appropriate antibiotics but only 14% for those receiving inappropriate antibiotics. Moreover, this retrospective
analysis of *Pseudomonas* bacteremia cases indicated that in cases where optimal antimicrobial therapy was delayed (24–48 hours), the healing rate decreased from 74% to 46%. Surgery may be necessary in case of important necrosis, or abscess. In the event of important neutropaenia, the addition of granulocytic colony-stimulating factor should be discussed.10

### 4 | CONCLUSION

The diagnosis of EG should be evoked in front of maculopapular lesions rapidly evolving to necrotic ulcers, particularly in the presence of prolonged neutropaenia or other hematological malignancies.

**CONFLICT OF INTEREST**

No potential conflict of interest was reported by the authors.

**AUTHORS CONTRIBUTION**

All authors: contributed to all aspects of the manuscript.

**ORCID**

François Aubin [https://orcid.org/0000-0002-1421-4996](https://orcid.org/0000-0002-1421-4996)

**REFERENCES**

1. Korte A, Vos JM. Ecthyma gangrenosum. *N Engl J Med*. 2017;377:e32.
2. Martínez-Longoria CA, Rosales-Solis GM, Ocampo-Garza J, Guerrero-González GA, Ocampo-Candiani J. Ecthyma gangrenosum: a report of eight cases. *An Bras Dermatol*. 2017;92:698-700.
3. Güçlüer H, Ergun T, Demircay Z. Ecthyma gangrenosum. *Int J Dermatol*. 1999;38:299-302.
4. Goolamali SI, Fogo A, Killian L, et al. Ecthyma gangrenosum: an important feature of pseudomonal sepsis in a previously well child. *Clin Exp Dermatol*. 2009;34:180-182.
5. Betens S, Delaere B, Glupczynski Y, Schoevaerdts D, Swine C. Ecthyma gangrenosum in a non-neutropaenic, elderly patient: case report and review of the literature. *Acta Clin Belg*. 2008;63:394-397.
6. Ferguson L, Chong H, Singh M. Ecthyma gangrenosum without bacteraemia: evidence in favour of a broader definition. *Clin Exp Dermatol*. 2017;42:324-327.
7. Vaiman M, Lazarovitch T, Heller L, Lotan G. Ecthyma gangrenosum and ecthyma-like lesions: review article. *Eur J Clin Microbiol Infect Dis*. 2015;34:633-639.
8. Singh N, Devi M, Devi S. Ecthyma gangrenosum: a rare cutaneous manifestation caused by *Pseudomonas aeruginosa* without bacteraemia in a leukemic patient. *Indian J Dermatol Venereol Leprol*. 2005;71:128-129.
9. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. *Arch Intern Med*. 1985;145:1621-1629.
10. Bécherel PA, Chosidow O, Berger E, et al. Granulocyte-macrophage colony-stimulating factor in the management of severe ecthyma gangrenosum related to myelodysplastic syndrome. *Arch Dermatol*. 1995;131:892-894.

**How to cite this article:** Zanella A, Faure C, Merle C, Charollais R, Aubin F. Localized ecthyma gangrenosum without sepsis in a neutropenic patient with a myelodysplastic syndrome—Refractory anemia with excess blasts type 2. *Clin Case Rep*. 2019;7:1754–1756. [https://doi.org/10.1002/ccr3.2314](https://doi.org/10.1002/ccr3.2314)